Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial

Camrelizumab is an antibody against programmed death protein 1. We assessed the activity and safety of camrelizumab plus apatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, in patients with advanced cervical cancer. METHODS: This multicenter, open-label, single-ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Lan, Chunyan, Shen, Jingxian, Wang, Yin, Li, Jundong, Liu, Zhimin, He, Mian, Cao, Xinping, Ling, Jiayu, Huang, Jiaming, Zheng, Min, Zou, Guorong, Yan, Haowen, Liu, Qing, Yang, Fan, Wei, Wei, Deng, Yanhong, Xiong, Ying, Huang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768345/
https://www.ncbi.nlm.nih.gov/pubmed/33052760
http://dx.doi.org/10.1200/JCO.20.01920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768345/
https://www.ncbi.nlm.nih.gov/pubmed/33052760
http://dx.doi.org/10.1200/JCO.20.01920

Ejemplares similares